Results 191 to 200 of about 7,520 (210)
Some of the next articles are maybe not open access.
Pharmacokinetic profile of tamsulosin OCAS
BJU International, 2006The tamsulosin oral‐controlled absorption system (OCAS®) is a new tablet formulation of the α1‐adrenoceptor (α1‐AR) antagonist tamsulosin, which is used for treating lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).
Christopher R. Chapple +1 more
openaire +2 more sources
Tamsulosin: current clinical experience
Urology, 2001During the past decade, our understanding of the epidemiology and natural history of benign prostatic hyperplasia (BPH) has improved considerably. Population-based studies confirm that lower urinary tract symptoms (LUTS) are very common among aging men.
openaire +3 more sources
Toch tamsulosine bij urinesteenlijden?
Huisarts en wetenschap, 2017De huisarts behandelt regelmatig patienten met een koliekaanval door een urinesteen. De recent vernieuwde NHG-Standaard Urinesteenlijden beveelt het gebruik van alfablokker tamsulosine niet meer aan. Maar een nieuwe systematische review concludeert dat alfablokkers wel zorgen voor een snellere steenpassage en minder pijn.
openaire +2 more sources
Asymmetric Formal Synthesis of (-)-Formoterol and (-)-Tamsulosin
HETEROCYCLES, 2007AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
Seung Whan Ko +4 more
openaire +3 more sources
Chiral separation of tamsulosin by capillary electrophoresis
Journal of Pharmaceutical and Biomedical Analysis, 2005Enantiomers of (+/-) 5-[2 (R,S)-{[2-(o-ethoxyphenoxy) ethyl] amino} propyl]-2-methoxy-benzenesulfonamide (tamsulosin, drug frequently used in the treatment of prostate diseases) were separated by capillary electrophoresis (CE). An acidic background electrolyte (BGE) with sulfated-beta-cyclodextrin (S-beta-CD) was used to create a chiral separation ...
Jan Petr +5 more
openaire +3 more sources
Tamsulosin for the Treatment of Benign Prostatic Hypertrophy
The Annals of Pharmacotherapy, 2000OBJECTIVE: To review the information necessary to assess the efficacy and safety of tamsulosin compared with other adrenergic antagonists for treatment of symptomatic benign prostatic hyperplasia. DATA SOURCES: A search was conducted of Cumulated Index Medicus, January 1993–August 1999, which was restricted to human trials and English-language journals.
openaire +2 more sources
Tamsulosin and the Intraoperative Floppy Iris Syndrome
JAMA, 2009THE INTRAOPERATIVE FLOPPY IRIS SYNDROME (IFIS) was first described by Chang and Campbell in 2005. These authors and others observed that there was a tendency for poor pupillary dilation and the intraoperative triad of the billowing of a flaccid iris, the propensity for iris prolapse, and progressive intraoperative pupillary constriction. In the current
openaire +3 more sources
Tamsulosin and Iris Pigmentation
Ophthalmology, 2010Julio González Martín-Moro +2 more
openaire +3 more sources
Variations in intake of tamsulosin
Journal of Cataract and Refractive Surgery, 2007Shyamanga Borooah, Vikas Chadha
openaire +3 more sources
Efficacy and safety of tamsulosin OCAS
BJU International, 2006The efficacy and safety of a new tablet formulation of tamsulosin (the oral‐controlled absorption system: OCAS®) have been assessed in several clinical trials. In a phase IIb and a phase IIIa trial, the appropriate dose of the tamsulosin tablet for clinical practice was determined.
openaire +2 more sources